Coverage Guide · Updated April 28, 2026
Does Tricare Cover Ozempic? (2026 Coverage Guide)
Sometimes covered, varies by plan for Tricare members in 2026. Ozempic is FDA-approved for type 2 diabetes. Coverage depends on your specific plan, employer benefits, and prior authorization rules.
1. Tricare coverage status for Ozempic
| Detail | Status |
|---|---|
| Plan type | Military |
| Coverage status | Sometimes covered, varies by plan |
| FDA indication | type 2 diabetes |
| List price | $968/mo (cash-pay retail) |
| Manufacturer direct | NovoCare cash-pay, about $499/mo |
| Appeal success rate | ~35% when denied |
2. Tricare's coverage rules
Tricare covers GLP-1s for FDA-approved indications (type 2 diabetes for Mounjaro/Ozempic, chronic weight management for Wegovy/Zepbound). Prior authorization required. BMI 30+ or 27+ with comorbidity typical threshold.
3. Prior authorization requirements
Most Tricare plans require:
- BMI 30+ (or 27+ with at least one comorbidity such as type 2 diabetes, hypertension, sleep apnea, or non-alcoholic fatty liver disease)
- Documented prior weight-loss attempts (often 6 months of supervised diet and exercise)
- No contraindications (medullary thyroid carcinoma history, MEN-2)
- Type 2 diabetes diagnosis with elevated A1C (typically 6.5+)
- Some plans require step therapy through a cheaper drug first (often phentermine or metformin)
Prior auth approval typically takes 3 to 14 days. Some prescribers offer PA submission as part of the visit, which speeds the process.
4. If denied: how to appeal
Tricare appeals succeed about 35% of the time when prepared properly. Steps:
- Request the formal denial letter (your right under federal law). It will list the specific reason for denial.
- Have your prescriber write a letter of medical necessity. Should document BMI, comorbidities, prior weight-loss attempts, contraindications to cheaper alternatives, and any cardiovascular risk factors.
- Submit the appeal within the deadline (usually 30 to 180 days depending on plan).
- If denied at first appeal, escalate to second-level review or external review.
5. If uncovered: cheapest alternatives for Tricare members
- NovoCare cash-pay: about $499/mo. Direct from the manufacturer, no insurance required.
- Manufacturer savings card: as low as $25/mo for eligible commercial-insurance patients. Does not apply to Tricare plans.
- Compounded semaglutide: $80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide. Cash-pay only.
- Switch to the weight-loss-indicated version (Zepbound or Wegovy) if appropriate, which may have better coverage on plans with obesity benefits.
FAQ
Does Tricare cover Ozempic in 2026?
Sometimes covered, varies by plan for Tricare members. Ozempic is FDA-approved for type 2 diabetes. Coverage depends on your specific plan, employer benefits (for commercial plans), and prior authorization requirements. Tricare covers GLP-1s for FDA-approved indications (type 2 diabetes for Mounjaro/Ozempic, chronic weight management for Wegovy/Zepbound). Prior authorization required. BMI 30+ or 27+ with comorbidity typical threshold.
What is the prior authorization process for Ozempic on Tricare?
Most Tricare plans require: BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts (often 6 months), no contraindications, and sometimes step therapy through cheaper drugs first. Approval usually takes 3 to 14 days.
If Tricare denies Ozempic, can I appeal?
Yes. Tricare appeal success rate for GLP-1 denials is approximately 35%. Strongest appeals document BMI, comorbidities (diabetes, hypertension, sleep apnea, NAFLD), prior weight-loss attempts, and any contraindications to alternative drugs.
If insurance won't cover Ozempic, what is the cheapest alternative?
Three options. First, NovoCare cash-pay from the manufacturer at about $499/mo. Second, the manufacturer savings card if you have commercial insurance ($25/mo for eligible patients). Third, compounded semaglutide from a licensed compounding pharmacy ($80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide).